Shah, T., Poleski, M., Branch, S., Jowell, P., Obando, J., & Liddle, R. (2011). Aprepitant, a Neurokinin-1 Receptor Antagonist, for Prevention of Post-ERCP Pancreatitis in High Risk Patients: A Randomized, Double-blind, Placebo Controlled Trial. In American Journal of Gastroenterology (Vol. 106, pp. S54–S54). Ovid Technologies (Wolters Kluwer Health). https://doi.org/10.14309/00000434-201110002-00133

Shah, Tilak, Martin Poleski, Stanley Branch, Paul Jowell, Jorge Obando, and Rodger Liddle. “Aprepitant, a Neurokinin-1 Receptor Antagonist, for Prevention of Post-ERCP Pancreatitis in High Risk Patients: A Randomized, Double-blind, Placebo Controlled Trial.” In American Journal of Gastroenterology, 106:S54–S54. Ovid Technologies (Wolters Kluwer Health), 2011. https://doi.org/10.14309/00000434-201110002-00133.

Shah T, Poleski M, Branch S, Jowell P, Obando J, Liddle R. Aprepitant, a Neurokinin-1 Receptor Antagonist, for Prevention of Post-ERCP Pancreatitis in High Risk Patients: A Randomized, Double-blind, Placebo Controlled Trial. In: American Journal of Gastroenterology. Ovid Technologies (Wolters Kluwer Health); 2011. p. S54–S54.

Shah, Tilak, et al. “Aprepitant, a Neurokinin-1 Receptor Antagonist, for Prevention of Post-ERCP Pancreatitis in High Risk Patients: A Randomized, Double-blind, Placebo Controlled Trial.” American Journal of Gastroenterology, vol. 106, Ovid Technologies (Wolters Kluwer Health), 2011, pp. S54–S54. Crossref, doi:10.14309/00000434-201110002-00133.

Shah T, Poleski M, Branch S, Jowell P, Obando J, Liddle R. Aprepitant, a Neurokinin-1 Receptor Antagonist, for Prevention of Post-ERCP Pancreatitis in High Risk Patients: A Randomized, Double-blind, Placebo Controlled Trial. American Journal of Gastroenterology. Ovid Technologies (Wolters Kluwer Health); 2011. p. S54–S54.